Literature DB >> 21692849

Investigating the role of CD38 and functionally related molecular risk factors in the CLL NOD/SCID xenograft model.

Semra Aydin1, Florian Grabellus, Lewin Eisele, Michael Möllmann, Maher Hanoun, Peter Ebeling, Thomas Moritz, Alexander Carpinteiro, Holger Nückel, Ali Sak, Joachim R Göthert, Ulrich Dührsen, Jan Dürig.   

Abstract

We explored the role of CD38 and functionally associated molecular risk factors in a recently described chronic lymphocytic leukemia (CLL) nonobese diabetic/ severe combined immunodeficient xenograft model. Intravenous injection of peripheral blood mononuclear cells from 73 patients with CLL into 244 mice resulted in robust engraftment of leukemic cells into the murine spleens detected 4 wks after transplantation. Leukemic cell engraftment correlated significantly (P < 0.05) with markers reflecting disease activity, e.g., Binet stage and lymphocyte doubling time, and the expression of molecular risk factors including CD38, CD49d, ZAP-70, and IgVH mutational status. Increased engraftment levels of CD38+ as compared to CD38- CLL cells could be attributed, in part, to leukemic cell proliferation as evidenced by combined immunostaining of murine spleen sections for Ki-67 and CD20. In short-term (24 h) homing assays, CD38+ CLL cells migrated more efficiently to the bone marrow of the recipient animals than their CD38- counterparts. Finally, CD38 expression by the leukemic cells was found to be dynamic in that it was regulated not only by elements of the murine microenvironment but also by co-engrafting non-malignant human T cells. This model could be useful for evaluating the biological basis of CLL growth in the context of the hematopoietic microenvironment as well as preclinical testing of novel compounds.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21692849     DOI: 10.1111/j.1600-0609.2011.01626.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  10 in total

1.  Humanized mouse G6 anti-idiotypic monoclonal antibody has therapeutic potential against IGHV1-69 germline gene-based B-CLL.

Authors:  De-Kuan Chang; Vinodh B Kurella; Subhabrata Biswas; Yuval Avnir; Jianhua Sui; Xueqian Wang; Jiusong Sun; Yanyan Wang; Madhura Panditrao; Eric Peterson; Aimee Tallarico; Stacey Fernandes; Margaret Goodall; Quan Zhu; Jennifer R Brown; Roy Jefferis; Wayne A Marasco
Journal:  MAbs       Date:  2016-03-10       Impact factor: 5.857

2.  CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia.

Authors:  Paolo Strati; Sameer A Parikh; Kari G Chaffee; Sara J Achenbach; Susan L Slager; Timothy G Call; Wei Ding; Diane F Jelinek; Curtis A Hanson; Neil E Kay; Tait D Shanafelt
Journal:  Br J Haematol       Date:  2017-04-07       Impact factor: 6.998

Review 3.  In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing.

Authors:  Eva Hoferkova; Sona Kadakova; Marek Mraz
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

Review 4.  Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.

Authors:  Yair Herishanu; Ben-Zion Katz; Andrew Lipsky; Adrian Wiestner
Journal:  Hematol Oncol Clin North Am       Date:  2013-04       Impact factor: 3.722

Review 5.  Animal models of leukemia: any closer to the real thing?

Authors:  Guerry J Cook; Timothy S Pardee
Journal:  Cancer Metastasis Rev       Date:  2013-06       Impact factor: 9.264

6.  A Detailed Analysis of Parameters Supporting the Engraftment and Growth of Chronic Lymphocytic Leukemia Cells in Immune-Deficient Mice.

Authors:  Piers E M Patten; Gerardo Ferrer; Shih-Shih Chen; Jonathan E Kolitz; Kanti R Rai; Steven L Allen; Jacqueline C Barrientos; Nikolaos Ioannou; Alan G Ramsay; Nicholas Chiorazzi
Journal:  Front Immunol       Date:  2021-03-09       Impact factor: 7.561

Review 7.  Overview of the Use of Murine Models in Leukemia and Lymphoma Research.

Authors:  Rebecca Kohnken; Pierluigi Porcu; Anjali Mishra
Journal:  Front Oncol       Date:  2017-02-20       Impact factor: 6.244

8.  Optimized Xenograft Protocol for Chronic Lymphocytic Leukemia Results in High Engraftment Efficiency for All CLL Subgroups.

Authors:  Sarah Decker; Anabel Zwick; Shifa Khaja Saleem; Sandra Kissel; Andres Rettig; Konrad Aumann; Christine Dierks
Journal:  Int J Mol Sci       Date:  2019-12-12       Impact factor: 5.923

9.  Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy.

Authors:  S E M Herman; X Sun; E M McAuley; M M Hsieh; S Pittaluga; M Raffeld; D Liu; K Keyvanfar; C M Chapman; J Chen; J J Buggy; G Aue; J F Tisdale; P Pérez-Galán; A Wiestner
Journal:  Leukemia       Date:  2013-04-26       Impact factor: 11.528

Review 10.  The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia.

Authors:  Gabriele Brachtl; Josefina Piñón Hofbauer; Richard Greil; Tanja Nicole Hartmann
Journal:  Ann Hematol       Date:  2013-11-28       Impact factor: 3.673

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.